105 The paradoxical association between inherited factor VII deficiency and venous thrombosis.

S Marty, C Barro, B Chatelain, B Fimbel, B Triboud, J Reynaud, JF Schved, M Giansily-Blaizot

Haemophilia 2008; 1-7

 

106 Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.

G Cayla, JC Macia, F Roubille, H Rabesandratana, C Piot, JF Schved,

F Leclercq.

Circulation Journal 2008; 72: 2098-2100

 

107 Flow cytometric assessment of vasodilatation-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes.

G Cayla, JC Macia, H Rabesandratana, F Roubille, R Gervasconi,

JL Pasquié, E Barbotte, JF Schved, F Leclercq

Archives of Cardiovascular Diseases 2008; 101: 743-751

 

108Characteristics, mechanisms of action and epitope mapping of anti-factor VIII antibodies.

G Lavigne-Lissalde, C Rothschild, C Pouplard, P Lapalud, Y Gruel,

JF Schved, C Granier

Clinical  Review in Allergy and  Immunology 2009 ; 37: 67-79. Review

 

109 Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

C Bret, D Hose, T Reme, AC Sprynski, K Mahtouk, JF Schved, P Quittet,

JF Rossi, H Goldschmidt, B Klein.

British Journal of Haematology 2009; 145: 350-368

 

110 Common susceptibility allele are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from the GWAS approach.

            DA Tregouet, S Heath, N Saut, C Biron-Andréani, JF Schved, G Pernod,

            P Galand, L Drouet, D Zelenika, I Juhan-Vague, MC Alessi, L Tiret,

            M Lathrop, J Emmerich, P Morange.

            Blood 2009; 113: 5298-5303

 

111 Major differences in bleeding symptoms between factor VII deficiency and haemophilia B.

               F Bernardi, A Dolce, M Pinotti, AD Shapiro, E Santagostino, F Peyvandi,

               A Batorova, M  Lapecorella, JF Schved,J Ingerslev, G Mariani; for the          International Factor VII Deficiency Study Group.

               Journal of  Thrombosis and Haemostasis 2009; 7: 774-779

 

112 Prevalence of the jak2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.

               S Tondeur, S Boutruche, C Biron-Andréani, JF Schved.

               Thrombosis Haemostasis 2009; 101: 787-789

 

113 The Southern French registry of genetic hemochromatosis: a tool for determination of clinical prevalence of the disorder and genotype penetrance.

            P Aguilar-Martinez, M Bismuth, F Blanc, P Blanc, S Cunat, O Dereure,

P Dujols, M Giansily-Blaizot, C Jorgensen,  A Konate, D Larrey,

A Le Quellec, T Mura, I  Raingeard , J Ramos, E Renard, F Rousseau,

JF Schved, MC Picot.

            Haematologica 2010;95: 551-556

 

114 Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal haemoglobinuria receiving eculizumab.

            D Helley, R Peffault de Latour,Raphaël Porcher, C Arrais Rodrigues,

            I Galy‑Fauroux, J Matheron, A Duval, JF Schved,AMFischer, G Socié

            Haematologica 2010; 95: 574-581

115 A follow-up study of a genome-wide association scan identifies a new venous thrombosis susceptibility locus on chromosome 6p24.1 .

PE Morange,  I Bezemer, N Saut, L Bare, G Burgos, J Brocheton, H Durand, C Biron-Andréani,JF Schved, G Pernod, P Galan, L Drouet, D Zelenika, M Germain, V Nicaud, S Heath, E Ninio, A Delluc, T Münzel, T Zeller,SM Brand-Herrmann, MC Alessi, L Tiret, M Lathrop, F Cambien, S Blankenberg, J Emmerich, DA Trégouët,FR Rosendaal

            American Journal of Human Genetics 2010;86: 595-595

116 Expression map of the human exome in CD34+ cells and blood cells: increased alternative splicing in cell motility and immune response genes.

            S Tondeur, C Pangault, T Le Carrour, Y Lannay, R Benmahdi, A Cubizolle,

            S Assou, V Pantesco, B Klein, JF Schved, T Fest, J De Vos.

            Plos One 2010; 5: 1-10

 

117 Comprehensive pediatric cares of rare bleeding disorders.

            M Giansily-Blaizot & JF Schved.

            Pediatric Health 2010; 4: 209-217

 

118 Recombinant activated factor VII for surgery in factor VII deficiency: a prospective evaluation – The surgical STER.

            G Mariani, A Dolce, A Batorova, G Auerswald, JF Schved, S Siragusa,

            M Napolitano, JB Knudsen, J Ingerslev on behalf of the STER and the       International Factor VII Deficiency Study Group.

            British Journal of Haematology 2010; 152: 340-346

 

 

 

119 A multi-stage design strategy provides strong evidence that the BAI3 locus is associated with early onset venous thromboembolism.

            G Antoni, P Morange, Y Luo, N Saut, S Heath, M Germain, C Biron-Andréani,    JF Schved, G Pernod, P Galan, D Zelenika, MC Alessi, L Drouet, S Visvikis-        Siest, PS Wells, M Lathrop, J Emmerich, DA Tregouet, F Gagnon

            Journal of Thrombosis and Haemostasis 2010; 12: 2671-2679

 

 

120 Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study.

            P Fontana, P Berdague, C Castelli, C Nolli, I Barazer, I Fabbro-Perray,

            JF Schved, H Bounameaux, F Mach, P de Moerloose, JL Reny.

            Journal of Thrombosis and Haemostasis 2010; 12: 2614-2623

121Iron overload in HFE C282Y heterozygotes at first genetic             testing: a strategy for identifying rare HFE variants.

P Aguilar-Martinez , B Grandchamp, S Cunat, F Cadet , F Blanc,  M Nourrit , K Lassoued, JF Schved, J Rochette.

            Haematologica 2011; 96:507-514.

 

122  Gene expression profile of ADAMs and ADAMTSs metalloproteinases in normal and malignant plasma cells and in the bone marrow environment.

C Bret, D Hose, T Rème, A Kassambara, A Seckinger,T Meissner, JF Schved, T Kanouni, H Goldschmidt, B Klein.

             Experimental  Hematolology 2011; 39:546-557

 

123A retrospective analysis of 157 surgical procedures performed without replacement therapy in 83 unrelated factor VII-deficient patients.

            F  Benlakhal, T Mura, JF Schved, M. Giansily-Blaizot

            on behalf of the French Study Group of Factor VII deficiency

            Journal of Thrombosis and Haemostasis 2011;9:1149-1156.

 

124 Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.

            P Fontana R, James, I Barazer, P Berdagué, JF Schved, M  Rebsamen,

            N Vuilleumier, JL Reny.

            Journal of Thrombosis and Haemostasis 2011; 9:1664-1666.

           

125 SULFs in human neoplasia: implication as progression and prognosis factors.

            C Bret, J  Moreaux, JF  Schved, D  Hose, B Klein.

            Journal of Translational Medicine 2011;9:72.

 

126 Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors.

            A Lebreton, P Lapalud, H Chambost, C Biron-Andréani, PE Morange,

C Combescure, AMarquès-Verdier, C Berger, JFSchved, C  Granier,

G Lavigne-Lissalde.

            Thrombosis Haemostasis 2011 ; 105:954-961.

 

127Answer to a few notes of precaution.

            JF Schved.

            Haemophilia 2011, Published on line

           

128 Discontinuous epitopes on the C2 domain of coagulation factor VIII mapped by computer-designed synthetic peptides.

            A Lebreton, V Moreau, P Lapalud, C Cayzac, JF Schved, G Lavigne,

            C Granier

            British Journal of Hematology 2011; 155: 487-97

                       

129  Scuba diving is possible and safe for patients with hemophilia.

            JF Schved, M De Haro, M Drapeau, M Schved.

            Haemophilia 2012; 18: 75 – 79

 

130 Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European network of rare bleeding disorders.

            F Peyvandi, R Palla, M Menegatti, SM Siboni, S Halimeh, B Faeser,

            H Pergantou, H Platokouti, P Giangrande, K Peerlinck, T Celkan, N Ozdemir,    C Bidlingmaier, J Ingerslev, M Giansily-Blaizot, JF Schved, R Gilmore,

            A Gadisseur, M Benedik-Dolnicar, L Kitanovski, D Mikovic, KM Musallam,         FR Rosendaal, on behalf of the European Network of Rare Bleeding Disorders           (EN-RBD) Group      

            Journal of Thrombosis and Haemostasis 2012; 10: 615-621

 

131 Registry of hemophilia and other bleeding disorders in Syria

            T Ali, JF Schved

Hemophilia 2012; 18, 851-854

 

132 Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the ADRIE study.

            JL Reny, P Berdague, A Poncet, I Barazer, S Nolli, P Fabbro-Perray,

            JF Schved, H Bounameaux, F Mach, P de Moerloose, P Fontana

            Circulation 2012; 125: 3201-3210

 

133 Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous?

               M Giansily-Blaizot, S Marty, SW Chen, JL Pellequer, JF Schved

               Thrombosis Research 2012. Suppl 1:S47-49

 

134 The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.

            P Lapalud, T Ali, C Cayzac, E Mathieu-Dupas, H Levesque, C Pfeiffer,

J Balicchi, Y Gruel, J Borg, JF Schved, C Granier, G Lavigne-Lissalde.

            Journal of Thrombosis and Haemostasis 2012; 10:1814-1822

 

135 Homozygous mutation of the 5'UTR region of the L-Ferritin gene in the hereditary hyperferritinemia-cataract syndrome and its impact on the phenotype.

M  Giansily-Blaizot, S Cunat, G Moulis, JF Schved, P Aguilar-Martinez.

Haematologica 2013; 98 : e42-3.)

 

 

136 Seven Treatment Evaluation Registry (STER) and the International Factor VII Deficiency Study Groups. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.

G Mariani, M Napolitano, A Dolce, R Pérez Garrido, A Batorova, M Karimi, H Platokouki, G Auerswald, AM Bertrand, G Di Minno, JF Schved, J Bjerre, J Ingerslev, B Sørensen, A Ruiz-Saez.

 Thrombosis Haemostasis 2013; 109: 238-247

 

 

137 Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER.

M Napolitano, M Giansily-Blaizot, A Dolce, JF Schved, G Auerswald, J Ingerslev, J Bjerre, C Altisent, P Charoenkwan, L Michaels , A Chuansumrit, G Di Minno, U Caliskan, G Mariani.

Haematologica 2013; 98: 538 - 544

 

138 Pre-interventional haemostatic assessment. Guidelines from the French Society of Anaesthesia and Intensive Care.

F Bonhomme, N Ajzenberg, JF Schved, S Molliex, CM Samama for the French Anaesthesic and Intensive Care Committee on evaluation of routine preoperating testing

European Journal of Anaesthesiology 2013; 30: 1 – 21

 

139 Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013.

G Pernod, P Albaladejo, A Godier, CM Samama, S Susen, Y Gruel, N Blais, P Fontana, A Cohen, JV Llau, N Rosencher, JF Schved, E de Maistre, MM Samama , P Mismetti, P Sié.

Archives of  Cardiovascular  Diseases, accepté pour publication mai 2013

 

140 Management of cardiovascular disease in haemophilia.

G Cayla, PE Morange, H Chambost, JF Schved

Thrombosis  Research, accepté pour publication  juin  2013

 

 

PUBLICATIONS INTERNATIONALES DANS LE CADRE D'ETUDES MULTICENTRIQUE

 

 

M1 Critical discussion of the assessment of a three stage prognostic classification for chronic Lymphocytic leukemia.

            C Chastang, P Travade, A Auquier and the Cooperative group on CLL of the       Société Française d’Hématologie.

            Statistics in Medicine  1985, 4 : 287-293

 

M2 Effectiveness of CHOP regimen in advanced untreated chronic lymphocytic leukemia.

            French Cooperative Group on Chronic Lymphocytic Leukemia.

            The Lancet  1986, i : 1346-1349

 

M3 Patient accrual and interim statistical analysis in long-term randomized clinical trials: The French Chronic Lymphocytic Leukemia CLL 80 protocol as a case study.

            C Chastang, P Travade, J Benichou, G Dighiero, JL Binet and the French           Cooperative Group on Chronic Lymphocytic Leukemia.

Statistics in Medicine1986; 5: 465-473

 

M4 French registry on acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria.

            Groupe Français de morphologie hématologique

Cancer 1987, 60, 6 : 1385-1394

 

M5 Prognostivc and therapeutic advances in CLLmanagement: the experience of the French Cooperative Group.

            French Cooperative Group on Chronic Lymphocytic Leukemia.

            Seminars in Hematology1987,24,4:275-290.

 

M6 New trends in CLL treatment

            P Travade, C Chastang, G Dighiero, JL Binetand the French

            Cooperative Group on Chronic Lymphocytic Leukemia.

            Blood Cells 1987,12:485-496.

 

M7 Anticoagulants circulants en dehors de l’hémophilie

            Enquête multicentrique conduite par le secrétariat de la Société Française de       Médecine Interne

            Revue de Médecine Interne 1988,9:33-39.

 

M8 Comparison of the (A,B,C) staging and the RAI’s staging from a large prospective series (953 patients)

            French Cooperative Group on Chronic Lymphocytic Leukemia

            Nouvelle Revue Française d'Hématologie 1988,30:363-367.

 

M9 CHOP regimen versus intermittent chlorambucil-prednisone in stage B chronic lymphocytic leukemia.

            French Cooperative Group on Chronic Lymphocytic Leukemia

            Nouvelle Revue Française d'Hématologie 1988,30:449-452.

 

M10 Therapy of chronic lymphocytic leukemia.

            French Cooperative Group on Chronic Lymphocytic Leukemia

            Nouvelle Revue Française d'Hématologie 1988,30:443-48.

 

M11 Traitement des thromboses veineuses constituées. Etude comparative d’un fragment d’héparine de bas poids moléculaire ( Fragmine) administrée par voie sous-cutanée et de l’héparine standard administrée par voie intra-veineuse continue.

            Etude multicentrique

            Revue de Médecine Interne 1989,10:375-381.

 

M12 Epidemiology of aplstic anemia in France: a prospective multicentric study.

            JY Mary, E Baumelou, M Guiguet and the French Cooperative Group for

            epidemiological study of aplastic anemia.

            Blood 1990,75,8:1646-1653.

 

M13 Long term results of the CHOP regimen in stage C chronic lymphocytic leukemia.

French Cooperative Group on Chronic Lymphocytic Leukemia.

            British Journal of Haematology 1989,73,334-340.

 

M14 Effects of chlorambucil in initial forms of chronic lymphocytic leukemia (stage A) : results of a randomized clinical trial on 612 patients.

French Cooperative Group on Chronic Lymphocytic Leukemia

            Blood1990,75,7:1414-1421.

 

M15 A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia.

French Cooperative Group on Chronic Lymphocytic Leukemia

            Blood 1990,75,7:1422-1425.

 

M16 Natural history of a stage A chronic lymphocytic leukemia untreated patients.

French Cooperative Group on Chronic Lymphocytic Leukemia.

            British Journal of Haematology1990,76,45-57.

 

M17 Unresolved issues in chronic lymphocytic leukemia treatment.

French Cooperative Group on Chronic Lymphocytic Leukemia.

            LeukemiaLymphoma 1991,5(S):79-81.

 

M18 Therapeutic results from the trials managed by the French cooperative group on chronic lymphocytic leukemia.

French Cooperative Group on Chronic Lymphocytic Leukemia.

            LeukemiaLymphoma 1991,5(S):83-88.

 

M19 Epidemiology of aplastic anemia in France: a case-control study. I. Medical  history and medication use.

            JY Mary, E Baumelou, M Guiguet and the French Cooperative Group for

            epidemiological study of aplastic anemia.

            Blood1993,81,6:1471-1478.

 

M20 Recombinant interferon alpha 2b combined with a doxorubicin-containing regimen in advanced follicular lymphoma patients.

            P Solal-Seligny, E Lepage, N Brousse and the Groupe d’étude des

            lymphomes de l’adulte.

            New England Journal of Medicine 1993, 329: 1608-1614

 

M21 Adjsuted versus fixed doses of the low-molecular weight heparin fragmin in the treatment of deep vein thrombosis.

            M Alhenc-Gelas, C Jestin-Le Guernic, JF Vitoux, A Kher, M Aïach,

            JN Fiessinger for the Fragmin-study group.

            Thrombosis Haemostasis 1994, 71: 698-702

 

M22 French multicentric evaluation of recombinant tissue factor ( Recombiplastin) for determination of the prothrombin time.

            J Roussi, L Drouet, M Samama, P Sié.

            Participants: C Bal, L Boudaoud, JP Cazenave, MH Denninger,

Ch Droule, MH Horellou, G Lévy, E Mazoyer, J  Sampol,

JF Schved, C Vergnes.

            Thrombosis Haemostasis 1994, 72: 698-704

 

M23 Pratiques cliniques lors du diagnostic : enquête française et recommandations . Le purpura thrombocytopénique autoimmun.

            JP Marie, D Simon, E Baumelou, S Bellucci, Ph Bierling, D Bordessoule,

            T Leblanc, M Leporrier, JM Miclea, Y Najean, JD Rain, P Rohrlich,

            JF Schved, R Zittoun.

La PresseMédicale 1997, 26, 9: 433-438

 

M24 Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene.

            D Meyer, E Fressinaud, C Gaucher, JM Lavergne, L Hilbert, AS Ribba,

            S Jorieux, C Mazurier and the INSERM network on molecular abnormalities        in von Willebrand disease.

            Thrombosis Haemostasis 1997; 78, 1: 451-456

 

M25 Inhibitor incidence in French previously untreated patients with severe hemophilia a receiving recombinant factor VIII (rFVIII)

            CRotschild, YLaurian,EPSartre, ABorel-Derlon, H Chambost, PMoreau,

J Goudemand, A Parquet, J Peynet, M Vicariot, P Beurrier, S Claeyssens,

A Durin, AFaradji, E Fressinaud, S Gaillard, V Guerin, C Guerois, G Pernod, P Pouzol, JF Schved, C Gazengel

            Thrombosis Haemostasis 1998; 80: 779-783

 

M26 The lupus ratio test – An interlaboratory study on the detection of lupus anticoagulant by an APTT-based, integrated, and semi-quatitative test.

            EM Jacobsen, L Barna-Chier, JM Taylor, DA Triplett, F Wisloff from the Fifth     International survey of Lupus anticoagulants- ISLA 5.

            Thrombosis Haemostasis 2000; 83: 704-708

 

M27 Clinical Manifestations management and molecular genetics in congenital factor VII deficiency: The international registry on congenital factor VII deficiency

            GMariani ,FH Herrmann ,FBernardi, JF Schved, G Auerswald, J Ingerslev.

            Blood 2000; 96: 374

 

M28 Low Molecular Weight heparine and unfractionated heparin in thrombosis prophylaxis: Meta-analysis based on the original patient data.

            Armin Koch, Sandra Ziegler, Heike Breitscherwerdt

            Thrombosis Research, 2001;102 :295-309.

 

M29 Venous Thromboembolism in asymptomatic carriers of Facor V Leiden mutation from symptomatic families: any role for hormonal replacement treament?

            The Procare Group(C Biron-Andréani corresponding author)

            Journal of Thrombosis and Haemostasis 2003; 1: 1325-1326

 

M30 Is recurrent venous thromboembolism more frequent in homozygous patients forthe factor V Leiden mutation than in heterozygous patients?

            The Procare Group

(C Biron-Andréani corresponding author)

Blood Coagulation and Fibrinolysis 2003; 14: 523-529

 

M31 Perioperative platelet transfusion. Recommendations of the French hHealth Products Safety Agency (AFSSAPS)

            CM Samama, R Djoudi, T Lecompte, N Nathan, JF Schved

            MinervaAnesthesiologica 2006; 72: 447-452

M32 Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.

P Sié , CM Samama, A Godier ,N Rosencher , A Steib , JV Llau , P Van der Linden , G Pernod , T Lecompte , I Gouin-Thibault , P Albaladejo ; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis.

Archives of Cardiovascular  Diseases2011 ; 104:669-76.

 

M 33 Coagulation factor activity and clinical bleeding severity in rare bleeding disorders : results from the European Network of Rare Bleeding disorders.

            F Peyvandi, R Palla, M Menegatti, SM Siboni, S Halimeh, B Faeser,

H Pergantou, H Plakotouki, P Giangrande, K Peerlinck, T Celkan,

N Ozdemir, C Bidling Maier, J Ingerslev, M Giansily-Blaizot, JF Schved, R Gilmore, A Gadisseur, M Benedink-Dolnicar, L Kitanovski, D Mikovic, KM Musallam and F Rosendaal on behalf of the European Network of Rare Bleeding Disorders ( EN-RBD) group

            Journal of Thrombosis and Haemostasis 2012; 10: 615-621

 

 

 

LIVRES, ARTICLES OU CHAPITRES DE LIVRES

 

L1 Internat Hématologie.

            JF Schved, JC Gris.

            Fascicule destiné à la préparation du Concours d’Internat

            Ed Méditions, Lyon 1986

 

L2 Effect of physical training and smoking cessation on PAI levels.

            JC Gris, JF Schved.

In P Gls-Greenwalt, ed. Fibrinolysis in disease. The malignant process, interventions in thrombogenic mechanisms, and novel treatment modalities. New York: CRC Press, 1995: 84-90

 

L3  Marqueurs biologiques d’états préthrombotiques et de thrombose.

            JF Schved, JC Gris.

In  J Sampol, D Arnoux, B Boutière, Ed. Manuel d'Hémostase. Paris: Option Bio, 1995

 

L4  Hémostase et infection par le virus de l’immunodéficience humaine

            JC Gris, JF Schved.

In  J Sampol, D Arnoux, B Boutière. Manuel d'Hémostase.

Ed. Option Bio, Paris 1995

 

L5 Le processus d’hémostase : conception actuelle.

            JF Schved

In B Dartayet. Communications Scientifiques MAPAR 96

 Ed. MAPAR, Le Kremlin Bicêtre 1996

 

L6 XIVth International congress on thrombosis

            Guest Editors: S Lévy-Toledano, J Conard, JF Schved

            Haemostasis 1996, 26 S3, 232p

 

L7 Les nouvelles anomalies constitutionnelles prédisposant aux thromboses veineuses.

            JF Schved, C Biron

            in: Y Najean. Traité d'Hématologie

Ed. Ellipse, Paris 1999

 

L8 Procoagulant activities.

            JF Schved

            in: A Bikfavi. Vascular Biology and Pathology:

Encyclopedy Reference Book.Ed. Springer Verlag (à paraître)

 

L9 Les variables préanalytiques en hémostase

            Recommandations du Groupe d'Etudes sur l'Hémostase et la Thrombose

(GEHT)

            Numéro spécial Sang Thrombose Vaisseaux , Février 1998.

Ouvrage collectif GEHT

            Coordination du numéro: JF Schved

 

L10 Thrombopénies induites par l’héparine

            JF Schved

in: F D'Athis. XXVème Journées Méditerranéennes d'Anesthésie Réanimation Urgences

Ed Sauramps, Montpellier 1999: p 119-126

 

L11 Inherited factor VII deficiency: basis of a multicentric study.

            M Giansily, C Biron, P Aguilar-Martinez, JF Schved

            in: Y Sultan. Plasmatic or Recombinant F VIII,

 Ed Springer, Paris 1999: p 47-51

 

L12 Hémophilies.

            C Biron, JF Schved.

            in: G Sébahoun. Hématologie Clinique et Biologique

            Ed Arnette, Vélizy 1999: p 413 - 418

 

L13 Réussir l’internat : Hématologie.

Ouvrage Collectif rédigé par L'Association Interrégionale pour l'Enseignement de l'Hématologie (AIPEH)

Coordination du livre: JF Schved

            Editions Ellipse, Paris 1999

 

L14 Utilisation des traitements antithrombotiques en pratique médicale courante Recommandations du Groupe d'Etudes sur l'Hémostase et la Thrombose(GEHT).

            Numéro spécial Sang Thrombose Vaisseaux , Octobre 2000

Ouvrage collectif GEHT

            Coordination du numéro: B Boneu, JF Schved, T Lecompte,

MC Alessi.

 

Tissue factor and tissue factor pathway inhibitor: from fundamental to clinic.

            JF Schved, M Giansily-Blaizot

In: Pathophysiological, Clinical and Laboratory aspects of Thromboembolic Disease. Proceedings of the 8th Advanced Teaching Course of the European Thrombosis Research Organization (ETRO), 2001: 81-86

 

L15 Hémophilie et médecine de rééducation.

            - Coordination de l'ouvrage : P Codine, C Biron-Andréani,

JF Schved,  C Hérisson.

            Masson Ed, Paris 2004, 163 pages

 

            - Rédaction de 2 chapitres:

            . Hémophilie: de la génétique à la clinique

                        JF Schved, C Biron-Andréanip.1-6

 

- Quels sports pour l'hémophile?

JF Schved, C Fondanesche p. 131-140

 

L16  Hémophilies.

            C Biron, JF Schved.

            in: G Sébahoun. Hématologie Clinique et Biologique

            Ed Arnette, Vélizy 2005: p 429 - 434

 

L17 Maladies hémorragiques par déficit constitutionnel en facteurs de coagulation en dehors de l'hémophilie et de la maladie de Willebrand

JF Schved

In: MM Samama et Coll.Hémorragies et Thromboses. Du Diagnostic au traitement. Ed. Masson , Paris 2006: p 52 -63

 

L18 Hémophilie: physiopathologie et bases moléculaires.

            JF Schved

Encyclopédie Médico-chirurgicale. Ed. Elsevier Masson SAS, Paris2008: Hématologie, 13-021-B10: p1 - 14

 

L19 Traitements de l'hémophilie.

            JF Schved

Encyclopédie Médico-Chirurgicale.Ed. Elsevier Masson SAS, Paris 2008:  Hématologie, 13-021-B20: p 1-11

 

L20 Transfusion en hématologie.

            Coordination du livre:JJ Lefrère  et JF Schved

            Eds John LibbeyEurotext, Paris 2010

 

L21 La pratique du sport chez l’hémophile

            JF Schved

            In:  P Nguyen et Coll. L’hémophilie en question. Ed Médicales Phase 5,

            Paris 2011: p 38 - 42

 

L22 Le vieillissement de la population hémophile.

            JF Schved

            In:  P Nguyen et Coll. L’hémophilie en question. Ed Médicales Phase 5,

            Paris 2011: p 47 – 52

 

L23 Hémophilie et plongée

            JF Schved, M Schved, M Dauty, P Codine, M De Haro, B Flieller.

            Ed Bayer Schering Pharma Loos 2011: 65 pages

 

L24 Hémostase : physiologie et exploration en pratique courante.

            Avec N Ajzenberg, AM Fischer, Y Gruel, PE Morange.

            In: Hématologie . Société Française d’Hématologie. C Binet et

            M Zandeckicordonnateurs. Ed Elsevier  Masson, Paris 2011: p183-194

 

L25 Hémostase : prescription et surveillance d’un traitement antithrombotique.

            Avec N Ajzenberg, AM Fischer, Y Gruel, PE Morange.

            In: Hématologie . Société Française d’Hématologie. C Binet et

            M Zandecki cordonnateurs. Ed Elsevier  Masson, Paris 2011: p195-206

 

L26 Hémostase : accidents des anticoagulants.

            Avec N Ajzenberg, AM Fischer, Y Gruel, PE Morange.

            In: Hématologie . Société Française d’Hématologie. C Binet et

            M Zandecki coordonnateurs. Ed Elsevier  Masson, Paris 2011: p207-210

 

L27 Hémostase : troubles de l’hémostase et de la coagulation.

            Avec N Ajzenberg, AM Fischer, Y Gruel, PE Morange.

            In: Hématologie . Société Française d’Hématologie. C Binet et

            M Zandecki cordonnateurs. Ed Elsevier  Masson, Paris 2011: p211-226

 

L28 Physiopathologie : de la synovite à l’arthropathie.

JF Schved, in: Arthropathie de la cheville chez l’hémophile et prise en charge. JF Schved, F Bonnel, C Biron-Andréani, P Codine, A Cotton,

N Boutry, JG Asencio, C Leonardi.. Ed Bayer Healthcare , Loos 2011. P39-43.

 

L29 Prise en charge de l’arthropathie hémophilique

            JF Schved, in: Arthropathie de la cheville chez l’hémophile et prise en charge.JF Schved, F Bonnel, C Biron-Andréani, P Codine, A Cotton,

N Boutry, JG Asencio, C Leonardi.. Ed Bayer Healthcare , Loos 2011. P62-68

 

L30 The Blood

            CM Samama et JF Schved in:.. Handbook of Clinical Anesthesia

(3rd Edition).BJ Pollard.Hodder Arnold,  London 2011. p215-242

 

L31 Anémies en cancérologie. Mieux comprendre pour mieux aider.

P. Aguilar-Martinez, JF Schved, in:G Cartron. Anémie en cancérologie. Ed. John Libbey, Montrouge 2012.P 12-24